Year: 2021
Type: review
Abstract: Although chemotherapy, targeted therapy and endocrine therapy decrease rate of disease recurrence in most breast cancer patients, many patients exhibit acquired resistance. Hyperactivation of the PI3K/AKT/mTOR pathway is associated with drug resistance and cancer progression. Currently, a number of drugs targeting PI3K/AKT/mTOR are being investigated in clinical trials by combining them with standard therapies to overcome acquired resistance in breast cancer. In this review, we summarize the critical role of the PI3K/AKT/mTOR pathway in drug resistance, the development of PI3K/AKT/mTOR inhibitors, and strategies to overcome acquired resistance to standard therapies in breast cancer.
Source: Frontiers in Pharmacology
Authors: Chao Dong, Jiao Wu, Yin Chen, Jianyun Nie, Ceshi Chen
Language: English
Subfield: Molecular Biology
Domain: Life Sciences
Open Access status: gold
Estimated APC paid: $2,950
Awards: G1301301856, G1801798962, G2282654747, G3080630271, G4091208245, G4517979502, G5143413475, MST4激酶调控Wnt信号通路促进肠癌发生的功能和机制研究, G6796203603, G7119785135, E3泛素连接酶RNF126通过调节DNA损伤修复促进乳腺癌, 趋化因子受体CCR7在乳腺癌淋巴结转移过程中的作用和机制研究, 基于PxLPxL功能区结合的HDAC4与人类新基因CCDC8在乳腺癌中的相互作用及分子机制研究, G8456814568, GABRP对乳腺癌干细胞的调控作用及其机制研究
OpenAlex ID: W3138840859
